Treating atopic dermatitis
Pro Research Analysisby 
Searched over 200M research papers
Treating Atopic Dermatitis: Current and Emerging Therapies
Introduction to Atopic Dermatitis Treatment
Atopic dermatitis (AD) is a chronic, inflammatory skin condition characterized by intense itching and recurrent flare-ups. Effective management of AD involves a combination of therapies aimed at reducing inflammation, restoring skin barrier function, and alleviating symptoms. This article synthesizes recent research on various treatment modalities for AD, including topical agents, systemic therapies, and alternative treatments.
Topical Treatments for Atopic Dermatitis
Ruxolitinib Cream (JAK1/JAK2 Inhibitor)
Ruxolitinib cream, a selective Janus kinase (JAK)-1 and JAK2 inhibitor, has shown significant efficacy in treating AD. In a phase 2 study involving 307 adult patients, ruxolitinib cream (1.5% twice daily) demonstrated a 71.6% improvement in the Eczema Area and Severity Index (EASI) at Week 4 compared to 15.5% with the vehicle cream. Additionally, rapid reductions in itch were observed within 36 hours, and the treatment was well tolerated without significant application site reactions .
Hydrocortisone and Fig Fruit Extract
A clinical trial comparing the efficacy of fig fruit extract to hydrocortisone 1.0% in pediatric patients with mild to moderate AD found that fig fruit extract significantly reduced the SCORAD index, pruritus, and intensity scores. This suggests that fig fruit extract could be a viable alternative to low-potency corticosteroids in treating AD .
Barrier-Strengthening Moisturizers
Moisturizers play a crucial role in managing AD by improving skin barrier function. A study demonstrated that using a barrier-strengthening moisturizing cream can delay the relapse of AD, highlighting the importance of regular emollient use in maintaining skin health and preventing flare-ups .
Systemic Treatments for Atopic Dermatitis
Dupilumab and Other Biologics
Dupilumab, an IL-4 receptor blocker, is an effective systemic treatment for moderate to severe AD. It has been shown to significantly reduce symptoms and improve quality of life, although it is associated with potential ocular side effects. Other biologics targeting IL-13, IL-31, IL-33, and thymic stromal lymphopoietin (TSLP) are currently under investigation and show promise in treating AD 510.
Janus Kinase (JAK) Inhibitors
Oral JAK inhibitors, such as baricitinib, upadacitinib, and abrocitinib, have shown outstanding efficacy in treating AD. These agents target key pathways in the atopic immune response and offer a new avenue for managing severe cases of AD. However, long-term safety data are still needed 810.
Alternative and Complementary Treatments
Synbiotics
Synbiotics, a combination of probiotics and prebiotics, have been studied for their potential in treating AD. A meta-analysis of randomized clinical trials found that synbiotics significantly reduced the SCORAD index in children aged 1 year or older when mixed bacterial strains were used. However, their efficacy in preventing AD remains inconclusive .
Natural Products
Natural products, including flavonoids, alkaloids, terpenes, and glycosides, have been explored for their anti-inflammatory properties in AD. Compounds such as puerarin, ferulic acid, and ginsenosides have shown potential in reducing inflammation by inhibiting key signaling pathways like JAK/STAT, MAPKs, and NF-κB .
Conclusion
The management of atopic dermatitis involves a multifaceted approach, combining topical treatments, systemic therapies, and alternative options to address the complex pathogenesis of the disease. Emerging treatments, particularly biologics and JAK inhibitors, offer promising new avenues for patients with moderate to severe AD. Continued research and personalized treatment strategies are essential to optimize outcomes and improve the quality of life for individuals with AD.
Sources and full results
Most relevant research papers on this topic
Treatment of Atopic Dermatitis With Ruxolitinib Cream (JAK1/JAK2 Inhibitor) or Triamcinolone Cream.
Ruxolitinib cream significantly reduced atopic dermatitis symptoms and rapidly decreased itch, supporting its potential addition to the topical armamentarium for AD.
Synbiotics for Prevention and Treatment of Atopic Dermatitis: A Meta-analysis of Randomized Clinical Trials.
Synbiotics show potential in reducing atopic dermatitis severity and reducing the risk of developing the condition in children aged 1 year or older.
A new topical treatment of atopic dermatitis in pediatric patients based on Ficus carica L. (Fig): A randomized, placebo-controlled clinical trial.
Fig fruit extract shows greater safety, efficacy, and symptom relief compared to hydrocortisone 1.0% in treating mild to moderate atopic dermatitis in children.
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children
Atopic dermatitis management should focus on prevention, hydration, and targeted topical treatments, with a focus on proactive therapy and individualized dietary recommendations.
Atopic Dermatitis: Diagnosis and Treatment.
Atopic dermatitis is effectively treated with topical corticosteroids, emollients, and ultraviolet phototherapy, with newer medications like crisaborole and dupilumab being cost-prohibitive for most patients.
Alternative Treatments for Atopic Dermatitis: An Update
Preliminary results show positive clinical effects for treatments like vitamin E, East Indian Sandalwood Oil, melatonin, l-histidine, and Manuka honey, but more evidence is needed to recommend their use in atopic dermatitis therapy.
Atopic Dermatitis in Childhood and Adolescence: Diagnosis and Treatment.
A combination of baseline therapy, reactive and proactive anti-inflammatory therapy, and systemic therapy as needed is the foundation for successful interdisciplinary treatment of atopic dermatitis in children and adolescents.
New Treatments in Atopic Dermatitis.
New topical and systemic therapies targeting the type 2 immune pathway show promise in revolutionizing atopic dermatitis management.
DOI